Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 30 Jul 2015 |
| Major shareholder announcement | 30 Jul 2015 |
| CORRECTION: Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint | 29 Jul 2015 |
| Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint | 29 Jul 2015 |
| Zealand announces total number of shares and voting rights in the company as of 30 June 2015 | 30 Jun 2015 |